Primal Pictures is part of Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 3rd Floor, Suite 1, 11-12 St. James’s Square, London, England SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Business as usual as Primal Pictures heads to new owner

As you may have seen, Pharma Intelligence (now rebranded as Citeline) – the parent brand of Primal Pictures – has moved to a new home. We are excited to share that we have joined Warburg Pincus and its portfolio of pharma, healthtech and information services companies and investments. In addition, Citeline has now signed a definitive agreement to merge with Norstella, another prominent pharmaceutical solutions provider.

 

We are as committed as ever to supporting you and/or your institutional needs and there are no changes to any aspect of our business or the service we deliver. Our team is here and ready to assist as normal. Our business and product development strategy will progress as planned. Improvements to our product suite, often based on user feedback, will continue. As will new product launches intended to deepen our groundbreaking anatomy learning solutions, such as Personal Profiles, Real-time Functional Anatomy and Primal’s Anatomy Learning Outcomes for Medicine.

 

Warburg Pincus is a long-established, global growth investor. As you can read in their announcement, the company is investing in Primal Pictures and Citeline to further power our future growth, expansion and innovation. This partnership will secure our ambition to optimize our products, data, technology and team, so we can bring more innovation, more support and more value to all our customers.

 

If you have any questions on this news, feel free to speak to your regular Primal Pictures contact or use this form.

 

We greatly value our ongoing relationship and look forward to continuing to support you into the future.